COPD and Lung Health

Huanghuan is doing Bachelor’s degree in English, Master’s degree in Social Work in SunYat-sen University in China.  Huanghuan was diagnosed with IPAH in 2005 and then got fired by a state-owned enterprises due to her illness. Even worse,with the progression of the disease, Huang took double lungs transplant twice. Luckily, she survived and lived a healthy life now. As a result, Huang began to organize on-line patient education programs in 2006 and finally turned it into a national patient organization in 2011. From then on,  Huang worked very hard  to advocate PH patients and lungs transplant patients equal access to medication and national insurance system. As conditions improved after 2019, Huang began to do research on  patients’ empowerment, shared-decision making and social inclusion.

Scientist and Clinician, NHS physician at the Royal Papworth Hospital Cambridge, discoverer of first effective therapies for Pulmonary Arterial Hypertension [PAH] (iv. Prostacyclin and Inhaled NO). Established the UK National Network of PAH centres. Professor, Medicine Sheffield University Medical School and Senior Principal Scientist AstraZeneca plc, Corporate Clinical Director Chiesi Farmaceutici (Italy), Architect of the first triple inhaler for asthma/COPD Trimbow®, Senior Partner TranScrip LLP, R&D Director Allergy Therapeutics plc, Vice President, and President Faculty of Pharmaceutical Medicine Royal Colleges of Medicine UK. CEO and founder of Camcon Robotics Ltd.

Jack Caravanos, life in the field ranges from jumping onto a motorcycle and navigating the jungles of Madre de Dios in the Peruvian Amazon studying toxic substances to traveling to remotes areas in Zambia, Indonesia, and Bolivia studying lead and other toxic wastes. By cooperating with local governments, his work provides safe, healthy, and evidence-based solutions for pollution problems in low- and middle-income countries. In partnership with Pure Earth, an international non-profit organization, Caravanos is studying the impact of gold extraction with mercury in Peru and Indonesia. Since miners are in danger of mercury poisoning, his research team is planning interventions that teach safer techniques for gold extraction. In Kabwe, Zambia - a mining town with exposure to lead - his research will provide methods to institute safer mining practices and policy recommendations to improve environmental remediation laws. Caravanos teaches Environmental Health for graduate students and Environmental Health in a Global World for undergraduate students. He also provides opportunities for student researchers in his ongoing projects, including in Indonesia and Ghana.

Brian T. Regan serves as Chief Strategy Officer for Grignard Pure, LLC, an innovative science and technology company developing next-generation solutions for eliminating airborne pathogens in all indoor environments from healthcare, to food processing, to workplaces, schools, and homes. He is responsible for shaping and executing Grignard Pure’s go-to-market strategy, integrating science, IP, regulatory, product development and partner engagement into successful implementation. Prior to joining Grignard Pure in January 2021, he spent twenty-five years working with organizations from start-ups to Fortune 500 companies, helping position them for optimal competitiveness in the markets they serve. Among those companies he counseled include Virgin, EMC, CA Technologies, Intuit, MongoDB, Docusign, and Philips.

Rivkees is a Professor of the Practice of Health Services, Policy, and Practice in the School of Public Health. He served as Florida's State Surgeon General and Secretary of Health from 2019 to 2021. Before moving to Florida, he served as a professor of pediatrics with tenure at Yale University. Dr. Rivkees has had more than 35 years of continuous research funding from the National Institutes of Health. He was responsible for the safety alert on liver toxicity caused by the antithyroid drug propylthiouracil. This led to major international treatment practice changes.